BMY•benzinga•
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
Summary
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2025 by benzinga